KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biolife Solutions (BLFS) Research & Development (2016 - 2025)

Biolife Solutions (BLFS) has disclosed Research & Development for 16 consecutive years, with -$66000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 94.7% to -$66000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $7.6 million, a 54.16% increase, with the full-year FY2025 number at $7.6 million, up 59.25% from a year prior.
  • Research & Development was -$66000.0 for Q4 2025 at Biolife Solutions, down from $2.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $4.2 million in Q4 2022 to a low of -$8.9 million in Q4 2023.
  • A 5-year average of $2.1 million and a median of $2.9 million in 2021 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 106.16% in 2021, then plummeted 313.3% in 2023.
  • Biolife Solutions' Research & Development stood at $3.6 million in 2021, then rose by 16.61% to $4.2 million in 2022, then tumbled by 313.3% to -$8.9 million in 2023, then surged by 85.97% to -$1.2 million in 2024, then soared by 94.7% to -$66000.0 in 2025.
  • Per Business Quant, the three most recent readings for BLFS's Research & Development are -$66000.0 (Q4 2025), $2.7 million (Q3 2025), and $2.7 million (Q2 2025).